OncoCyte Corp (NYSEAMERICAN:OCX) was the target of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 828,304 shares, a growth of 6.1% from the April 15th total of 780,426 shares. Approximately 2.8% of the shares of the company are sold short. Based on an average trading volume of 126,270 shares, the short-interest ratio is currently 6.6 days.
Several hedge funds have recently made changes to their positions in OCX. ExodusPoint Capital Management LP bought a new stake in shares of OncoCyte during the 1st quarter valued at $41,000. Jane Street Group LLC bought a new stake in shares of OncoCyte during the 1st quarter valued at $47,000. Charles Schwab Investment Management Inc. bought a new stake in shares of OncoCyte during the 1st quarter valued at $53,000. Citigroup Inc. bought a new stake in shares of OncoCyte during the 1st quarter valued at $82,000. Finally, Perkins Capital Management Inc. bought a new stake in shares of OncoCyte during the 1st quarter valued at $99,000.
OCX has been the topic of several recent research reports. Chardan Capital reiterated a “buy” rating and issued a $8.00 price target on shares of OncoCyte in a research report on Tuesday, April 2nd. Lake Street Capital increased their price target on shares of OncoCyte from $4.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, January 29th. Janney Montgomery Scott upgraded shares of OncoCyte from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 29th. Zacks Investment Research upgraded shares of OncoCyte from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Friday, January 25th. Finally, Piper Jaffray Companies initiated coverage on shares of OncoCyte in a research report on Wednesday, February 13th. They issued an “overweight” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $6.00.
OncoCyte (NYSEAMERICAN:OCX) last announced its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01.
TRADEMARK VIOLATION NOTICE: This story was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/21/short-interest-in-oncocyte-corp-ocx-grows-by-6-1.html.
OncoCyte Company Profile
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Recommended Story: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.